Keynote II: Evolving Role of Neoadjuvant Immunotherapy in Curative Intent Head and Neck Cancer

There are many ongoing advances in neoadjuvant immunotherapy in curative-intent head and neck cancer, yet optimal incorporation and biomarkers remain undefined. There is an urgent need to keep medical oncologists, head and neck surgeons, and radiation oncologists who treat head and neck cancer informed regarding emerging data regarding neoadjuvant immunotherapy in this setting.

This educational activity will discuss the evolving role of neoadjuvant immunotherapy in head and neck cancer. The role of predictive biomarkers in the context of neoadjuvant immunotherapy in resectable head and neck cancer will be discussed. Ongoing clinical trials evaluating neoadjuvant immunotherapy will also be addressed.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the evolving literature regarding the role of immunotherapy in curative intent head and neck cancer.
  • Identify biomarkers in setting of neoadjuvant immunotherapy.
  • Identify ongoing prospective trial efforts to evaluate neoadjuvant immunotherapy.
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 Certificate of Attendance
    This activity was designated for 0.75 AMA PRA Category 1 Credit™.
Course opens: 
03/11/2024
Course expires: 
03/10/2026
Cost:
$0.00
Part of: 
2024 Multidisciplinary Head and Neck Cancers Symposium onDemand
Rating: 
0

Ari Rosenberg, MD, is employed by the University of Chicago and has no financial relationships with a commercial interest.

Ravindra Uppaluri, MD, PhD, is employed by Brigham and Women's Hospital and serves on the advisory board for Daichi-Sankyo, Merck and Regeneron.

All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 Certificate of Attendance
    This activity was designated for 0.75 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.